Date of publication: November 03, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : Booster and Additional Dose for the Prevention of COVID-19
Rapid Antigen Test Kits for the Diagnosis of COVID-19 (September 2021 Updates)
Date of publication: September 27, 2021 Objectives: Evidence Summary: Use of Rapid Antigen Test Kits for the Diagnosis of COVID-19 HTAC Recommendation Review:
Tenofovir/Lamivudine/Dolutegravir (TLD) for Treatment-Naive and Treatment-Experienced Adolescents and Adults Living with HIV
Date of publication: August 24, 2021 Approved by the Secretary of Health: September 01, 2021 Evidence Summary: Tenofovir/Lamivudine/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV Advisory on non-inclusion in PNF: https://bit.ly/PR_TLD HTAC Recommendation Review:
SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the Prevention of COVID-19 (July Updates)
Date of publication: July 30, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the Prevention of COVID-19 (July Updates)
Two-dose Inactivated Polio Vaccine (IPV) versus One-dose IPV for the prevention of Poliomyelitis
Date of publication: July 13, 2021 Evidence Summary: Two-dose Inactivated Polio Vaccine (IPV) versus One- dose IPV for the prevention of Poliomyelitis Advisory for Appeals on Preliminary Recommendation: https://bit.ly/CallforAppeals_2DoseIPVPNF HTAC Recommendation Review: